




# NATIONAL INSTITUTES OF HEALTH Technology Transfer Office

- Serves as the United States' Medical Research Agency
- NIH's Impact Worldwide:
  - Driving economic growth and productivity
  - Improving health by promoting treatment and prevention
- 27 Institutes and Centers
  - Each with its own disease focus
- Connects NIH researchers and external partners
  - Exclusive/Non-exclusive licenses
  - Clinical Validation (Clinical Trial Agreements; CTAs)
  - Co-Development (Cooperative Research and Development Agreements; CRADAs)
  - Low-cost Tools/Reagents (Material Transfer Agreements; MTAs)



## Licensing/Collaboration Agreements with the National Institutes of Health



- Address technology gaps
- Address knowledge gaps
- Enhance pipeline



**\$ Boost product commercialization**  
**\$ Expand addressable markets**

### NIH Value Proposition:

**Technical, Commercial,  
Economic Development**

- >\$7B Product sales from licensed NIH IP (2022)
- Numerous advantages to working with us:
  - ✓ 0% equity and 0-15% overhead rate
  - ✓ Won't take your IP
  - ✓ Validate your technology and/or test in humans
  - ✓ World-renowned researchers and resources
  - ✓ Prestige factor: Collaboration = higher company profile



Therapeutics



Diagnostics



Research Tools



Vaccines



Devices



Software



# Partnering with NIH Offers Significant Commercialization Potential

## Acquisition of Licensee

 **Kite** acquired by  **GILEAD** for US \$11B (2017)

## Funding of Licensee

 **Rakuten Medical** 2013 NCI License → \$654.70M Raised Series A – Series D

 **navrogen** 2020 NCI License → \$6.95M Seed Closing (2021)

 **CARGO THERAPEUTICS** 2022 NCI License → \$200M Series A (2023)

## Collaborators and Licensees

Organization	Product	2022 Worldwide Sales
 <b>MERCK</b>	 <b>GARDASIL</b>	US \$6.9B
 <b>Janssen</b>	 <b>PREZISTA</b> (darunavir) tablets	US \$1.9B
 <b>Takeda</b>	 <b>VELCADE</b> (bortezomib)	US \$1.7B
 <b>Eisai</b>	 <b>Halaven</b> (eribulin mesylate) Injection   0.5 mg/mL	US \$578M
 <b>abbvie</b> <b>Sobi</b> <b>AstraZeneca</b>	 <b>SYNAGIS</b> PALIVIZUMAB	US \$340M (est.)

## NIH Technology Portfolio

➤ Pre-clinical/clinical technologies available for licensing/collaboration:

- Small molecules
- Devices
- Vaccines
- Wearables and Digital health
- Biologics
- Diagnostics
- Software
- Research tools (cells, mice, etc.)

### Website


[www.techtransfer.nih.gov](http://www.techtransfer.nih.gov)

- Listserv distributions of new opportunities
- Technologies available for licensing and co-development

### General Inquiries

[NCITechTransfer@mail.nih.gov](mailto:NCITechTransfer@mail.nih.gov)



 Connect with the NIH

### Social Media



[www.linkedin.com/company/intramural-research-program-irp/](http://www.linkedin.com/company/intramural-research-program-irp/)



@NIHOTT